Background The goal of this study was to investigate whether ceftriaxone combination
therapy is associated with better clinical outcomes than respiratory fluoroquinolone …

Guidelines recommend intravenous (IV) ceftriaxone at a dose of 1–2 g/d as empirical
treatment in adults hospitalized with community acquired pneumonia (CAP), with the …

Objectives Ceftriaxone is recommended as first-line antibiotic treatment (with the addition of
macrolide) for hospitalised adults with community acquired pneumonia (CAP). Narrower …

Introduction Guidelines recommend respiratory fluoroquinolone monotherapy or β-lactam
plus macrolide combination therapy as first-line options for hospitalized adults with mild to …

Introduction: Ceftriaxone has been recommended as a first-line treatment for various
infections; however, the doses for pneumonia have not been a consensus in randomized …

Current guidelines recommend the use of ceftriaxone and sulbactam-ampicillin for the initial
treatment of community-acquired pneumonia (CAP). However, there are no clear data on …

BACKGROUND: Limited data exist on the effectiveness of ceftriaxone plus doxycycline in
the treatment of patients hospitalized with community‐acquired pneumonia (CAP) …

Background The majority of community-acquired pneumonia (CAP) patients (about 80%)
will be treated as outpatients, because therapy with a single agent will work. For the …

Objective To explore the perceptions of ED doctors regarding the use of ceftriaxone in
patients with community‐acquired pneumonia (CAP). Methods Face‐to‐face interviews …

Background: The choice of empirical antibiotic treatment for patients with community-
acquired pneumonia (CAP) who are admitted to non-intensive care unit (ICU) hospital wards …